The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.

Current Atherosclerosis Reports
Jean DavignonNabil G Seidah

Abstract

Pro-protein-convertase-subtilisin-kexin-9 (PCSK9) enhances the degradation of the low-density lipoprotein receptor (LDLR) that plays a major role in cholesterol homeostasis. Recent advances have revealed a large number of genetic variants of PCSK9 that may modulate plasma cholesterol levels either positively or negatively, therefore influencing the risk of atherosclerosis. Recognition of these mutants may have clinical implication in assessing severity of disease, prognosis, or response to drug therapy. PCSK9's expression, secretion, and plasma levels maybe modulated by the proprotein convertase furin, by natural inhibitors (annexin-A2), or influenced by lipid-altering agents such as statins, fibrates, ezetimibe, and berberine. It is now a prime target for therapy, prompting the development of various approaches to reduce its LDLR degrading activity, including antibody neutralization, anti-sense oligonucleotides such as phosphorothioates, locked nucleic acids, and RNA interference, and eventually small molecule inhibitors. Which one will be clinically applicable will depend on long-term effects, cost, and ease of administration.

References

May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Sep 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jay D HortonJoseph L Goldstein
Jan 17, 2004·Human Genetics·Kirsten M TimmsDonna M Shattuck
May 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Kara N Maxwell, Jan L Breslow
Apr 5, 2005·Proceedings of the National Academy of Sciences of the United States of America·Shirya RashidJay D Horton
Oct 15, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Rossi P NaoumovaAnne K Soutar
Jan 21, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Knut Erik BergeTrond P Leren
Feb 9, 2006·American Journal of Human Genetics·Ingrid K KotowskiHelen H Hobbs
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Mar 25, 2006·Science·Michael S Brown, Joseph L Goldstein
Mar 14, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Nabil G Seidah, Annik Prat
May 31, 2007·The Journal of Clinical Endocrinology and Metabolism·H LoweS J Silverberg
Nov 24, 2007·Journal of Lipid Research·Holly E CareskeyRobert J Konrad
Jan 16, 2008·Sub-cellular Biochemistry·M J HayesS E Moss
Feb 5, 2008·The Journal of Biological Chemistry·Sanae KourimatePhilippe Costet
Mar 22, 2008·Atherosclerosis·Jamie CameronKnut Erik Berge
Apr 26, 2008·Atherosclerosis·Aaron R FolsomUNKNOWN Atherosclerosis Risk in Communities (ARIC) Study Investigators
Jun 13, 2008·Lipids in Health and Disease·Janice MayneMichel Chrétien
Jul 31, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ahmed ZaidAnnik Prat
Aug 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Maria Frank-KamenetskyKevin Fitzgerald
Sep 19, 2008·The Journal of Biological Chemistry·Gaétan MayerNabil G Seidah
Dec 10, 2008·Expert Opinion on Therapeutic Targets·Nabil G Seidah
Mar 3, 2009·Atherosclerosis·Sarah E A LeighSteve E Humphries
Apr 9, 2009·The Journal of Clinical Endocrinology and Metabolism·Susan G LakoskiHelen H Hobbs
May 16, 2009·Proceedings of the National Academy of Sciences of the United States of America·Joyce C Y ChanSimon M Jackson
Jul 3, 2009·Journal of Lipid Research·Geneviève DubucJean Davignon
Jul 22, 2009·Atherosclerosis·Giuseppe Danilo NorataAlberico Luigi Catapano
Sep 10, 2009·Journal of Lipid Research·Jason S TrouttRobert J Konrad
May 8, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Bronwen HerbertAnne K Soutar

❮ Previous
Next ❯

Citations

Feb 4, 2014·Archives of Biochemistry and Biophysics·Catherine J WootenDayami Lopez
Dec 1, 2012·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Michel Chrétien
Oct 29, 2013·Annual Review of Pharmacology and Toxicology·Giuseppe Danilo NorataAlberico Luigi Catapano
Dec 14, 2011·Cellular and Molecular Life Sciences : CMLS·Magdalena DomonJoanna Bandorowicz-Pikula
Jan 23, 2013·Current Cardiology Reports·Rose Q DoGregory G Schwartz
Feb 6, 2016·Cardiovascular Drugs and Therapy·Yanhong GuoY Eugene Chen
Jul 3, 2013·The Canadian Journal of Cardiology·Robert Roberts
Jun 8, 2013·The Canadian Journal of Cardiology·Zuhier AwanAlexis Baass
Dec 23, 2011·Clinical Science·Allan D SnidermanCurt D Furberg
Jan 1, 2014·Archives of Cardiovascular Diseases·Michel Farnier
Nov 21, 2014·Journal of Atherosclerosis and Thrombosis·Sha Li, Jian-Jun Li
Aug 29, 2016·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Enrico Agabiti Rosei, Massimo Salvetti
Mar 24, 2017·PloS One·Artuela ÇakuFrancois Corbin
Mar 16, 2017·World Journal of Cardiology·Rahul ChaudharyAndrew Sumner
Dec 13, 2017·Expert Opinion on Drug Metabolism & Toxicology·Arrigo F G CiceroClaudio Borghi
Mar 15, 2014·Circulation Research·Nabil G SeidahMajambu Mbikay
Mar 21, 2019·Future Medicinal Chemistry·Antonio Lavecchia, Carmen Cerchia
Feb 23, 2019·Journal of Insurance Medicine·Alacia J Tarpley
Jun 12, 2012·Nature Reviews. Drug Discovery·Nabil G Seidah, Annik Prat
May 7, 2019·Expert Opinion on Pharmacotherapy·Arrigo F G CiceroClaudio Borghi
Sep 1, 2011·Expert Review of Endocrinology & Metabolism·André Marette, Gary Sweeney
Aug 31, 2014·EMBO Molecular Medicine·Rose Q DoGregory G Schwartz
Aug 11, 2019·Current Topics in Medicinal Chemistry·Bo ChenPengjun Zhao
May 31, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michel Farnier
May 7, 2014·The Journal of Biological Chemistry·Nis Borbye PedersenHenrik Clausen
Jan 18, 2018·Physiological Genomics·Maria Luisa Matey-HernandezCristina Menni
Jun 19, 2014·Journal of Cardiovascular Pharmacology and Therapeutics·Simona DraganMaciej Banach
Oct 10, 2018·Nature Communications·William SpoonerCatherine Chaillan Huntington
Sep 27, 2020·Cardiovascular Drugs and Therapy·Stephani C WangRobert S Rosenson
Dec 15, 2010·The Journal of Biological Chemistry·Taichi YamamotoRobert O Ryan
Nov 4, 2011·Analytical Chemistry·Hu ZhouDaniel Figeys

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

Expert Opinion on Therapeutic Targets
Nabil G Seidah
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
G TibollaAlberico Luigi Catapano
Proceedings of the National Academy of Sciences of the United States of America
Shirya RashidJay D Horton
© 2021 Meta ULC. All rights reserved